The dramatic finding that an antibody that inhibits interleukin-1b (IL-1b) can reduce the risk of heart attack and stroke is the first clinical evidence that tackling the inflammatory component of cardiovascular disease can benefit patients.

Para acessar a publicação na íntegra clique  aqui

Fonte: NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 10 OCTOBER 2017 893